Company Info

BlueSphere Bio

Drug Discovery & Development

Overview

BlueSphere Bio was founded to enable each patient's immune system to provide the ability to create their own personal adoptive cell therapy (ACT) to treat their cancer. Our vision is for every cancer patient to have a chance for a cure.

Our novel technology unlocks the potential of individualized T-cell therapy for the treatment of cancer by harnessing the specificity of each patient’s T cells for the unique molecular fingerprint of their own cancer.

Contributions

Contributors

Contributions

1 Contributions1 / 1

Cell Therapy

Fighting Solid Tumors by Targeting Neoantigens in a Personalized Manner

Mark Shlomchik, M.D., Ph.D.

BlueSphere Bio

PAO-06-022-CL-03Jun 06, 2022

1 / 1

2 Contributors1 / 1

David Apelian, Ph.D., M.D.

Chief Executive Officer

Mark Shlomchik, M.D., Ph.D.

Co-Founder and Chief Scientific Officer

1 / 1